Nilay Akagun

Dr. Nilay Akagun

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2025 in Ophthalmic and Physiological Optics
Verified
Journal Article
Closed access
NANilay Akagun
Nilay Akagun
UAUgur Emrah Altiparmak
Ugur Emrah Altiparmak

25 April 2025 in Turkish Journal of Ophthalmology
Verified
Journal Article
Open access
NANilay Akagun
Nilay Akagun
UAUgur Emrah Altiparmak
Ugur Emrah Altiparmak
Evaluation of Reasons for Discontinuation of Atropine 0.01% in Myopia Management: A Single-Center Retrospective Study from Türkiye - Turkish Journal of Ophthalmology

5 February 2025 in Turkish Journal of Ophthalmology
Verified
Journal Article
Open access
NANilay Akagun
Nilay Akagun
UAUgur Emrah Altiparmak
Ugur Emrah Altiparmak
To investigate whether the combination therapy of Myopi-X® peripheral progressive addition lenses (PAL; Novax®) and atropine 0.05% provides an additive effect compared to monotherapies with either Myopi-X® PAL or atropine 0.05%. This retrospective cross-sectional study reviewed the clinical records of 51 patients, categorized into three groups: 27 in the Myopi-X group, 13 in the atropine 0.05% group, and 11 in the combination therapy group using Myopi-X peripheral PAL with atropine 0.05%. Baseline characteristics, including age, cycloplegic spherical equivalent (SE), and axial length (AL), were compared between the groups. Twelve months after treatment initiation, changes in SE and AL were assessed and compared between the groups. Among the 51 patients analyzed, the baseline characteristics differed significantly between the groups, with the atropine 0.05% group showing a higher average age, longer AL, and lower SE compared to the other groups. After 12 months, no significant differences were found in SE changes between the treatment groups (p=0.35). Similarly, changes in AL did not significantly differ between the groups (p=0.10), although age had a significant impact on AL change (p=0.01). No significant differences were observed in pairwise comparisons of SE or AL changes between the groups. In this study, combining atropine 0.05% with Myopi-X PALs did not provide an additive benefit. The literature suggests that both treatments are effective in slowing myopia progression individually; however, in our study, their combination did not significantly improve SE progression or axial elongation compared to monotherapies. Further randomized studies with larger patient groups are needed to confirm these findings and assess long-term effects.

17 April 2025 in BMC Ophthalmology
Verified
Journal Article
Open access
PDF file
NANilay Akagun
Nilay Akagun
UAUgur Emrah Altiparmak
Ugur Emrah Altiparmak
The global prevalence of myopia is rising rapidly, with projections indicating that by 2050, half of the world’s population will be affected. High myopia is associated with an increased risk of sight-threatening complications, contributing to a substantial public health burden. Atropine 0.01% has been widely used for myopia control in non-Asian populations, supported by evidence demonstrating its efficacy. Myopi-X® lenses, designed to induce myopic defocus, represent an optical alternative to pharmacological intervention. Given that atropine requires monthly preparation, long-term adherence, and may cause mild side effects, (Myopi-X® Novax®) lenses offer a non-pharmacological option that may be preferable for some patients. This study compares the effectiveness of these two treatment strategies in comparison with single vision lenses to provide further insights into their role in myopia management. This retrospective observational study was conducted at Acıbadem Hospital, Ankara, between September 2022 and September 2023. A total of 128 patients aged 5 to 16 years with myopia were included and divided into three groups: peripheral progressive addition lenses (Myopi-X® Novax®), atropine 0.01%, and single vision lenses. Baseline characteristics, including age, gender, and axial length, were recorded. Cycloplegic autorefraction and axial length measurements were performed, and statistical analyses were conducted to assess changes in spherical equivalent refraction and axial length over 12 months. Additionally, the potential effects of baseline axial length, gender, and age group on spherical equivalent progression and axial length elongation were evaluated. Significant differences were observed among the treatment groups in changes in spherical equivalent refraction and axial length (p < 0.001). Both the Myopi-X® lenses and atropine 0.01% groups exhibited significantly less myopia progression compared to the single vision lenses group (p < 0.001 for both). However, no significant difference was observed between the Myopi-X® lenses and atropine 0.01% groups at 12 months (p = 0.79), and axial length changes remained comparable between these two groups (p = 0.76). Regarding potential confounding factors, age had a significant effect on spherical equivalent refraction progression, with older children experiencing less myopic progression (p = 0.02), whereas no significant effect was observed on axial length change (p = 0.11). Gender was not significantly associated with changes in spherical equivalent (p = 0.21) or axial length (p = 0.32). Similarly, baseline axial length showed no significant association with changes in spherical equivalent (p = 0.17) or axial length (p = 0.36). Both Myopi-X® lenses and atropine 0.01% effectively slowed myopia progression over 12 months compared to single vision lenses. Spherical equivalent progression and axial length elongation were comparable between these two treatment groups. Gender and baseline axial length did not significantly affect the outcomes, whereas older children exhibited less myopic progression in terms of spherical equivalent change. This study aimed to compare the clinical effectiveness of these two treatment strategies. Further studies with longer follow-up periods are required to evaluate the long-term sustainability of these effects.

1 January 2020 in Nigerian Journal of Clinical Practice
Verified
Journal Article
Open access
NANilay Akagun
Nilay Akagun
POPa Ozer
Pa Ozer
SGS Gazyagci
S Gazyagci
Best corrected visual acuity (BCVA) was 20/20 in the right eye and 20/200 in the left eye. Slit lamp examination revealed a central corneal epithelial defect on the left eye and the right eye was normal. Corneal epithelial defect appeared after left upper eyelid chalazion surgery and persisted for 2 months without any response to treatment with eye patching, bandage contact lenses, and artificial eyedrops. We started the treatment with ASD six times daily and preservative-free netilmicin eyedrops four times daily to prevent infection. The drops were used simultaneously with eyepatching for the first two days. The eye was left unpatched after the second day. The corneal epithelial defect resolved after 48 hours. We did not detect a new epithelial defect in the follow up visits. ASD is a quick, safe, and effective treatment option in persistent epithelial defect cases....

18 February 2026 in Turkish Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
NANilay Akagun
Nilay Akagun
UAUgur Emrah Altiparmak
Ugur Emrah Altiparmak
Real-World Comparison of the Effectiveness of Defocus Incorporated Multiple Segments and Myopi-X Spectacle Lenses for Myopia Control in Turkish Children: A Retrospective Study - Turkish Journal of Ophthalmology